Arcturus Therapeutics vs Capricor Therapeutics
ARCT and CAPR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARCT and CAPR compare
Capricor Therapeutics is the larger company, worth 2.5 times as much as Arcturus Therapeutics ($595M against $240M).
Arcturus Therapeutics scores higher on the StockData Score (9 against 5 for Capricor Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARCT | CAPR |
|---|---|---|
| Size and price | ||
| Market cap | $240M | $595M |
| Share price | $8.44 | $10.24 |
| Change, 1 year | −2.7% | 65.2% |
| Change, 5 years | −76.8% | 208% |
| Beta (5Y) | 2.15 | 1.20 |
| Employees | 111 | 231 |
| StockData Score | ||
| Total score | 9 (better) | 5 |
| Valuation score | 2 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 2 (better) | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 7.9× | – |
| P/B | 1.4× (better) | 2.8× |
| FCF yield | −26.0% | −22.3% (better) |
| Fair value | $8.80 | – |
| Margin of safety | 4.1% | – |
| Growth | ||
| Revenue growth (TTM) | −68.7% | – |
| Revenue growth, 5Y average | 53.8% | – |
| Profitability | ||
| Operating margin | −311% | – |
| Net margin | −286% | – |
| FCF margin | −205% | – |
| Return on equity | −44.4% (better) | −100% |
| Return on invested capital | −534% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 6.68 | 6.77 (better) |
| Altman Z-score | −1.05 | 0.26 (better) |
| Piotroski F-score | 2 | 3 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 87.9% | 67.6% |
| Held by insiders | 8.1% | 1.6% |
| Insider net buying, 12 months | – | −$8.4M |
| Short interest, % of float | 20.7% | 32.8% |
Go deeper
- ARCT stock overview
- ARCT income statement
- ARCT valuation and score
- CAPR stock overview
- CAPR income statement
- CAPR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.